Crucell Gains Contract Manufacturing Company With SBL Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition, valued at $50.5 mil., is expected to complete on Nov. 23.
You may also be interested in...
Crucell Inks European Distribution Deal With Sanquin For Cofact
Pact compliments April agreement with U.S. Bayer spin-off Talecris Biotherapeutics to distribute Prolastin.
Crucell Inks European Distribution Deal With Sanquin For Cofact
Pact compliments April agreement with U.S. Bayer spin-off Talecris Biotherapeutics to distribute Prolastin.
Merck Expands Vaccine Partnership With Crucell
Cross-licensing deal allows Merck to further leverage the Dutch biotech’s technology.